Fullerton Fund Management’s Biogen BIIB Stock Holding History

Fullerton Fund Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,734	Closed	-$374K	–	137
2024 Q1	$374K	Buy	+1,734	New	+$406K	0.02%	108

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fullerton Fund Management's BIIB Position: Q2 2024 in Review

Fullerton Fund Management sold out of Biogen (BIIB) in Q2 2024, closing a stake of 1,734 shares — an estimated $374K sold.

Fullerton Fund Management first reported a position in BIIB in Q1 2024 and held it in 1 quarter. The position peaked at $374K in Q1 2024. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Fullerton Fund Management reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Fullerton Fund Management sold 1,734 Biogen shares in Q2 2024, an estimated $374K.
Fullerton Fund Management first reported a position in Biogen in Q1 2024 and held it in 1 quarter.
Fullerton Fund Management's Biogen position peaked at $374K in Q1 2024.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Fullerton Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.